iBio, Inc. is a preclinical stage biotechnology company using Artificial Intelligence (AI) and machine learning (ML) to develop precision antibody therapeutics targeting obesity and cardiometabolic diseases. Key pipeline assets include IBIO-600 (anti-myostatin antibody) and IBIO-610 (Activin E antibody), developed via an AI-enabled epitope steering and antibody optimization platform. The company operates from a San Diego R&D laboratory and anticipates first human clinical trials in late fiscal 2026 or early fiscal 2027.
Q2 FY2026 — expected 2026-09-18
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-09-05 | 2025-06-30 | 0001558370-25-011888 | EDGAR | 89K words |
| 2024-09-20 | 2024-06-30 | 0001420720-24-000038 | EDGAR | — |
| 2023-09-27 | 2023-06-30 | 0001420720-23-000045 | EDGAR | — |
| 2022-10-11 | 2022-06-30 | 0001420720-22-000064 | EDGAR | — |
| 2021-09-28 | 2021-06-30 | 0001558370-21-012819 | EDGAR | — |
| 2020-10-13 | 2020-06-30 | 0001104659-20-114567 | EDGAR | — |
| 2019-08-26 | 2019-06-30 | 0001144204-19-041659 | EDGAR | — |
| 2018-09-18 | 2018-06-30 | 0001144204-18-049866 | EDGAR | — |
| 2017-09-15 | 2017-06-30 | 0001144204-17-048249 | EDGAR | — |
| 2016-10-13 | 2016-06-30 | 0001144204-16-127993 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-10 | 2025-12-31 | 0001420720-26-000004 | EDGAR | 37K words |
| 2025-11-12 | 2025-09-30 | 0001420720-25-000041 | EDGAR | — |
| 2025-05-02 | 2025-03-31 | 0001420720-25-000025 | EDGAR | — |
| 2025-02-10 | 2024-12-31 | 0001420720-25-000012 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001420720-24-000054 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0001420720-24-000020 | EDGAR | — |
| 2024-02-09 | 2023-12-31 | 0001558370-24-000934 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001558370-23-019043 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001558370-23-009707 | EDGAR | — |
| 2023-02-14 | 2022-12-31 | 0001420720-23-000009 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001558370-22-017874 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001420720-22-000024 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-09 | 0001420720-26-000006 | EDGAR | 5K words |
| 2026-02-27 | 0001104659-26-021654 | EDGAR | — |
| 2026-02-10 | 0001420720-26-000003 | EDGAR | — |
| 2026-01-12 | 0001104659-26-002940 | EDGAR | — |
| 2025-11-21 | 0001104659-25-114800 | EDGAR | — |
| 2025-11-17 | 0001420720-25-000045 | EDGAR | — |
| 2025-11-12 | 0001420720-25-000039 | EDGAR | — |
| 2025-11-04 | 0001420720-25-000035 | EDGAR | — |
| 2025-10-30 | 0001420720-25-000033 | EDGAR | — |
| 2025-09-05 | 0001558370-25-011885 | EDGAR | — |
370 total filings indexed. 338 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001420720 |
| Ticker | IBIO |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Headquarters | San Diego, California |
| Website | https://www.ibioinc.com |
| Listed | 2008-08-19 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report